2/2022
vol. 14
abstract:
Case report
High-dose-rate interstitial brachytherapy as a suitable option for metastatic extraskeletal myxoid chondrosarcoma – a case report
1.
Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan
2.
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
3.
Department of Medical Physics, National Cancer Center Hospital, Tokyo, Japan
4.
Department of Radiation Therapy Center, Shin-Matsudo Central General Hospital, Chiba, Japan
J Contemp Brachytherapy 2022; 14, 2: 198–204
Online publish date: 2022/03/31
We report on a patient with metastatic extraskeletal myxoid chondrosarcoma (EMC), who was treated with palliative high-dose-rate (HDR) interstitial brachytherapy (ISBT). The patient was an 87-year-old woman who underwent an amputation for a bulky tumor in her right ankle joint. EMC was histopathologically confirmed. She presented with a large right inguinal lymph node metastasis of EMC 16 months after surgery. Palliative HDR-ISBT (30 Gy/2 fractions in 1 day) for the right inguinal lymph node metastasis was administered to shorten treatment period. Additional HDR-ISBT (30 Gy/2 fractions in 1 day) was administered for the management of subsequent subcutaneous metastasis to the right breast and right popliteal fossa. HDR-ISBT provided significant long-term control of the recurrent tumor in all three sites, without severe acute and late toxicity. Thus, HDR-ISBT regimen of 30 Gy/2 fractions in 1 day can be a suitable option for both palliation and long-term local control for patients with metastatic EMC.
keywords:
extraskeletal myxoid chondrosarcoma, palliation, high-dose-rate, interstitial brachytherapy
|
|